Protara Therapeutics (FRA:1KPA) Cyclically Adjusted FCF per Share: € (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1KPA Protara Therapeutics Inc FRA:1KPA
34 GF Score
Price €3.16
! 3 Warning Signs
View Full Analysis

What is Protara Therapeutics Cyclically Adjusted FCF per Share?

Protara Therapeutics FRA:1KPA +6.26% 34 Cyclically Adjusted FCF per Share is € as of Jun. 2026. GuruFocus rates FRA:1KPA with a GF Score™ of 34/100. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Protara Therapeutics's adjusted free cash flow per share for the three months ended in Jun. 2026 was €-0.223. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-09-20), Protara Therapeutics's current stock price is €3.158. Protara Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was . Protara Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Protara Therapeutics  (FRA:1KPA) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Protara Therapeutics Cyclically Adjusted FCF per Share Related Terms


Protara Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Protara Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Protara Therapeutics Cyclically Adjusted FCF per Share Chart

Protara Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Protara Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

FRA:1KPA vs SLGL, GLSI, NERV: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Protara Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protara Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protara Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Protara Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


FRA:1KPA
34GF Score
Protara Therapeutics Inc FRA:1KPA
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Protara Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Protara Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.223/333.9520*333.9520
=-0.223

Current CPI (Jun. 2026) = 333.9520.

Protara Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -14.787 241.428 -20.454
201612 -13.884 241.432 -19.205
201703 -16.811 243.801 -23.027
201706 -6.438 244.955 -8.777
201709 -10.123 246.819 -13.697
201712 -10.907 246.524 -14.775
201803 -10.063 249.554 -13.466
201806 -19.996 251.989 -26.500
201809 -6.744 252.439 -8.922
201812 -8.694 251.233 -11.557
201903 -19.214 254.202 -25.242
201906 -19.415 256.143 -25.313
201909 -21.991 256.759 -28.602
201912 -15.853 256.974 -20.602
202003 -1.207 258.115 -1.562
202006 -0.891 257.797 -1.154
202009 -0.419 260.280 -0.538
202012 -0.520 260.474 -0.667
202103 -0.903 264.877 -1.138
202106 -0.724 271.696 -0.890
202109 -0.499 274.310 -0.607
202112 -0.608 278.802 -0.728
202203 -0.869 287.504 -1.009
202206 -0.475 296.311 -0.535
202209 -0.556 296.808 -0.626
202212 -0.416 296.797 -0.468
202303 -1.063 301.836 -1.176
202306 -0.750 305.109 -0.821
202309 -0.535 307.789 -0.580
202312 -0.740 306.746 -0.806
202403 -0.837 312.332 -0.895
202406 -0.342 314.175 -0.364
202409 -0.329 315.301 -0.348
202412 -0.357 315.605 -0.378
202503 -0.344 319.799 -0.359
202506 -0.232 322.561 -0.240
202509 -0.235 324.800 -0.242
202512 -0.320 324.054 -0.330
202603 -0.317 330.213 -0.321
202606 -0.223 333.952 -0.223

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of € mean?
Protara Therapeutics (FRA:1KPA) has a Cyclically Adjusted FCF per Share of € as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Protara Therapeutics and its competitors.
Is Protara Therapeutics' Cyclically Adjusted FCF per Share too high?
Protara Therapeutics' current Cyclically Adjusted FCF per Share is €. Overall, Protara Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Protara Therapeutics' Cyclically Adjusted FCF per Share compare to SLGL and GLSI?
Protara Therapeutics' Cyclically Adjusted FCF per Share of € can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Protara Therapeutics and its competitors. Protara Therapeutics's current Cyclically Adjusted FCF per Share is €. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protara Therapeutics stock overvalued right now?
Protara Therapeutics (FRA:1KPA) has a current Cyclically Adjusted FCF per Share of €. The current Cyclically Adjusted FCF per Share is €. Protara Therapeutics' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Protara Therapeutics (FRA:1KPA), the current Cyclically Adjusted FCF per Share is € as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Protara Therapeutics Business Description

Other Exchanges TARA:USA
Address 345 Park Avenue South, 3rd Floor, New York, NY, USA, 10010
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
34GF Score

Get the complete analysis for FRA:1KPA

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.16
Price